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ABSTRACT  24 
 25 
Background: A vaginal microbiota dominated by lactobacilli (particularly Lactobacillus crispatus) is 26 
associated with vaginal health, whereas a vaginal microbiota not dominated by lactobacilli is considered 27 
dysbiotic. Here we investigated whether L. crispatus strains isolated from the vaginal tract of women 28 
with Lactobacillus-dominated vaginal microbiota (LVM) are pheno- or genotypically distinct from L. 29 
crispatus strains isolated from vaginal samples with dysbiotic vaginal microbiota (DVM). 30 
 31 
Results: We studied 33 L. crispatus strains (n=16 from LVM; n=17 from DVM). Comparison of these two 32 
groups of strains showed that, although strain differences existed, both groups were 33 
heterofermentative, produced similar amounts of organic acids, inhibited Neisseria gonorrhoeae growth 34 
and did not produce biofilms. Comparative genomics analyses of 28 strains (n=12 LVM; n=16 DVM) 35 
revealed a novel, 3-fragmented glycosyltransferase gene that was more prevalent among strains 36 
isolated from DVM. Most L. crispatus strains showed growth on glycogen-supplemented growth media. 37 
Strains that showed less efficient (n=6) or no (n=1) growth on glycogen all carried N-terminal deletions 38 
(respectively, 29 and 37 amino acid-deletions) in a putative pullulanase type I gene. 39 
 40 
Discussion: L. crispatus strains isolated from LVM were not phenotypically distinct from L. crispatus 41 
strains isolated from DVM, however, the finding that the latter were more likely to carry a 3-fragmented 42 
glycosyltransferase gene may indicate a role for cell surface glycoconjugates, which may shape vaginal 43 
microbiota-host interactions. Furthermore, the observation that variation in the pullulanase type I gene 44 
associated with growth on glycogen discourages previous claims that L. crispatus cannot directly utilize 45 
glycogen.  46 
 47 
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The vaginal mucosa hosts a community of commensal, symbiotic and sometimes pathogenic micro-55 
organisms. Increasing evidence has shown that the bacteria within this community, referred to here as 56 
the vaginal microbiota (VM), play an important role in protecting the vaginal tract from pathogenic 57 
infection, which can have far reaching effects on a woman’s sexual and reproductive health [1, 2]. 58 
Several VM compositions have been described, including VM dominated by: 1) Lactobacillus iners; 2) L. 59 
crispatus; 3) L. gasseri; 4) L. jensenii and; 5) VM that are not dominated by a single bacterial species but 60 
rather consist of diverse anaerobic bacteria, including Gardnerella vaginalis and members of 61 
Lachnospiraceae and Leptotrichiaceaeprevotella [3-5]. Particularly VM that are dominated by L. 62 
crispatus are associated with vaginal health, whereas a VM consisting of diverse anaerobes – commonly 63 
referred to as vaginal dysbiosis - have been shown to increase a woman’s odds for developing bacterial 64 
vaginosis (BV), acquiring STI’s, including HIV, and having an adverse pregnancy outcome [1, 2, 4, 6].   65 
 66 
The application of human vaginal L. crispatus isolates as therapeutic agents to treat dysbiosis may have 67 
much potential [7, 8], but currently there are still many gaps in our knowledge concerning the 68 
importance of specific physiological properties of L. crispatus for a sustained domination on the mucosal 69 
surface of the vagina. Comparative genomics approaches offer a powerful tool to identify novel 70 
important physiological properties of bacterial strains. The genomes of nine human L. crispatus isolates 71 
have previously been studied, also in the context of vaginal dysbiosis [9, 10]. Comparative genomics of 72 
these strains showed that about 60% of orthologous groups (genes derived from the same ancestral 73 
gene) were conserved among all strains; i.e. comprising a ‘core’ genome [10]. The accessory genome was 74 
defined as genes shared by at least two strains, while unique genes are specific to a single strain. 75 
Currently it is unclear whether traits pertaining to in vivo dominance are shared by all strains (core 76 
genome), or only by a subset of strains (accessory genome). For example, both women with and without 77 
vaginal dysbiosis can be colonized with L. crispatus (see e.g.[11]) and we do not yet fully understand why 78 
in some women L. crispatus dominates and in others not. 79 
 80 
The following bacterial traits may be of importance for L. crispatus to successfully dominate the vaginal 81 
mucosa: 1) the formation of an extracellular matrix (biofilm) on the vaginal mucosal surface; 2) the 82 
production of antimicrobials such as lactic acid, bacteriocins and H2O2 that inhibit the growth and/or 83 
adhesion of urogenital pathogens; 3) efficient utilization of available nutrients – particularly glycogen, as 84 
this is the main carbon source in the vaginal lumen; and; 4)  the modulation of host-immunogenic 85 
responses. Considering these points, firstly, Ojala et al. [10] observed genomic islands encoding enzymes 86 
involved in exopolysacharide (EPS) biosynthesis in the accessory genome of L. crispatus and postulated 87 
that strain differences in this trait could contribute to differences in biofilm formation, adhesion and 88 
competitive exclusion of pathogens. Secondly, experiments have shown that L. crispatus effectively 89 
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inhibits urogenital pathogens through lactic acid production, but these studies included only strains 90 
originating from healthy women [12-16]. Abdelmaksoud et al. [9] compared L. crispatus strains isolated 91 
from Lactobacillus-dominated VM (LVM) with strains isolated from dysbiotic VM (DVM) and indeed 92 
observed decreased lactic acid production in one of the strains isolated from DVM, providing an 93 
explanation for its low abundance. However, no significant conclusion could be made as their study 94 
included only eight strains. Thirdly, there is a general consensus that vaginal lactobacilli (including L. 95 
crispatus) ferment glycogen thus producing lactic acid, but no actual evidence exists that L. crispatus  96 
produces the enzymes to directly degrade glycogen [10, 17]. Lastly, L. crispatus-dominated VM are 97 
associated with an anti-inflammatory vaginal cytokine profile [18, 19] and immune evasion is likely a 98 
crucial (but poorly studied) factor that allows L. crispatus to dominate the vaginal niche. A proposed 99 
underlying mechanism is that L. crispatus produces immunomodulatory molecules [20], but L. crispatus 100 
may also accomplish immune modulation by alternating its cell surface glycosylation, as has been 101 
suggested for gut commensals [21]. Taken together, there is a clear need to study the properties of more 102 
human (clinical) L. crispatus isolates to fully appreciate the diversity within this species.  103 
 104 
Here we investigated whether L. crispatus strains isolated from the vaginal tract of women with LVM are 105 
pheno- or genotypically distinct from L. crispatus strains isolated from vaginal samples with DVM, with 106 




Lactobacillus crispatus strain selection and whole genome sequencing 111 
For this study, 40 nurse-collected vaginal swabs were obtained from the Sexually Transmitted Infections 112 
clinic in Amsterdam, the Netherlands, from June to August 2012, as described previously by Dols et al. 113 
[4]. In total, 33 L. crispatus strains were isolated from these samples (n=16 from LVM samples; n=17 L. 114 
crispatus strains from DVM samples). Following whole genome sequencing, four contigs (n=3 strains 115 
from LVM; n=1 strains from DVM) were discarded as they had less than 50% coverage with other 116 
assemblies or with the reference genome (ST1), suggesting that these isolates belonged to a different 117 
Lactobacillus species. One contig (from a strain isolated from LVM) aligned to the reference genome, but 118 
its genome size was above the expected range, suggestive of contamination with a second strain and 119 
was therefore also discarded. The remaining 28 isolates (n=12 LVM and n=16 DVM) were assembled and 120 
used for comparative genomics. These genomes have been deposited at DDBJ/ENA/GenBank under the 121 
accession numbers NKKQ00000000-NKLR00000000. The versions described in this paper are versions 122 
NKKQ01000000-NKLR01000000 (Table 1). 123 
 124 
Lactobacillus crispatus pan genome 125 
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The 28 L. crispatus genomes had an average length of 2.31 Mbp (range 2.16 – 2.56 MB) (Table 1), which 126 
was slightly larger than the reference genome (ST1; 2.04Mbp). The GC content of the genomes was on 127 
average 36.8%, similar to other lactobacilli [10]. An average of 2099 genes were annotated per strain 128 
(Table 1; Figure 1). This set of 28 L. crispatus genomes comprised 4261 different gene families. The core 129 
genome consisted of 1429 genes (which corresponds to ~68% of a given genome) and the accessory 130 
genome averaged at 618 genes (~30%) per strain. Each strain had on average 54 unique genes (~2.0%). 131 
The number of accessory and unique genes did not significantly differ between strains isolated from 132 
LVM or from DVM, with respectively an average of 621 (range: 481-855) and 55 (range: 5-243) genes for 133 
LVM strains and 615 (range: 488-837) and 53 (range: 1-250) genes for DVM strains. The distribution of 134 
cluster of ortholog groups (COG) also did not differ between strains from Lactobacillus-dominated and 135 
DVM. The gene accumulation model [22] describes the expansion of the pan-genome as function of the 136 
number of genomes and estimated that this species has access to a larger gene pool than described 137 
here; the model estimated the L. crispatus pan genome to include 4384 genes. 138 
 139 
A fragmented glycosyltransferase gene was abundant among strains isolated from DVM  140 
In a comparative genomics analysis we aimed to identify genes that were specific to strains isolated from 141 
either LVM or DVM. We observed that three transposases, one of which was further classified as an IS30 142 
family transposase, were more abundant among strains isolated from DVM than among strains from 143 
LVM. IS30 transposases are associated with genomic instability and have previously been found to flank 144 
genomic deletions in commercial L. rhamnosus GG probiotic strains [23]. Most notably, we observed that 145 
strains from DVM were more likely to carry three gene fragments of a single glycosyltransferase (GT) 146 
than strains isolated from LVM. GTs are enzymes that are involved in the transfer of a sugar moiety to a 147 
substrate and are thus essential in synthesis of glycoconjugates like exopolysaccharides, glycoproteins 148 
and glycosylated teichoic acids [24, 25].  149 
 150 
The three differentially abundant GT gene fragments all align to different regions of a family 2 A-fold GT 151 
of the ST1 L. crispatus strain (CGA_000165885.1) and are flanked by other genes potentially encoding 152 
GTs (Figure 2). Fragment 1 aligns with 472 bp of the original unfragmented GT, while fragment 2 153 
overlaps with the last 3 bp of fragment 1 and fragment 3 overlaps 7 bp with fragment 2. Given that all 154 
these fragments align to the non-fragmented GT gene in in L. crispatus ST1, we hypothesize that the 155 
three fragments belong to the same GT. The L. crispatus genomes however contained a combination of 156 
one or more of the three GT fragments, while the surrounding genes were conserved among the strains. 157 
The first fragment of 510 bp contains the true GT fold domain and is thus responsible for the catalytic 158 
activity of the GT. The second and third fragment are considerably shorter, respectively 228 and 328 bp, 159 
and do not harbor any significant relation to a known GT-fold (Figure 3). Four different combinations of 160 
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GT fragments were observed in the studied genomes, namely a variant with: (1) no fragments, (2) all 161 
three fragments, (3) fragment 1 and 3, and (4) fragment 1 and 2 (Figure 2; Table 2).  162 
 163 
Strains isolated from LVM were not phenotypically distinct from strains isolated from DVM 164 
Phenotypic studies on the L. crispatus strains did not reveal any biofilm formation – as assessed by 165 
crystal violet assays, except for one strain (RL19) which produced a weak biofilm. In line with this, very 166 
low levels of autoaggregation (on average 5%) were observed and this also did not differ between the 167 
two groups of strains. Strain specific carbohydrate fermentation profiles were observed, as assessed by a 168 
commercial API CH50 test, but the distribution of these profiles did not relate to whether the strains 169 
were isolated from LVM or from DVM. Strains isolated from LVM produced similar amounts of organic 170 
acids compared with strains isolated from DVM when grown on chemically defined medium mimicking 171 
vaginal fluids [26]. The strains mainly produced lactic acid. Other acids such as succinate acid, butyric 172 
acid, glutamic acid, phenylalanine, isoleucine and tyrosine were also produced, but four-fold lower 173 
compared to lactic acid. Very small acidic molecules, such as acetic and propionic acid, were out of the 174 
detection range and could thus not be measured. We also assessed antimicrobial activity against a 175 
common urogenital pathogen Neisseria gonorrhoeae. Inhibition was similar for strains isolated from LVM 176 
and from DVM: N. gonorrhoeae growth was inhibited (i.e. lower OD600nm in stationary phase compared to 177 
the control), in a dose-dependent way, by on average 27.9 ± 15.8% for undiluted L. crispatus 178 
supernatants compared to the N. gonorrhoeae control. Undiluted neutralized L. crispatus supernatants 179 
inhibited N. gonorrhoeae growth by on average 15.7 ± 16.3% (Supplementary information).   180 
 181 
Strain-specific glycogen growth among both LVM and DVM isolates 182 
Of the 28 strains for which full genomes were available, we tested 25 strains (n=12 LVM and n=13 DVM) 183 
for growth on glycogen. We compared growth on glucose-free NYCIII medium supplemented with 184 
glycogen as carbon source to growth on NYCIII medium supplemented with glucose (positive control) 185 
and NYCIII medium supplemented with water (negative control). All except one strain (RL05) showed 186 
growth on glycogen; however six strains showed substantially less efficient growth on glycogen. One 187 
strain showed a longer lag time (RL19; on average 4.5 hours, compared to an average of 1.5 hours for 188 
other strains) and five strains (RL02, RL06, RL07, RL09 and RL26) showed a lower OD after 36 hours of 189 
growth compared to other strains (Figure 4). Growth on glycogen did not correlate to whether the strain 190 
was isolated from LVM or DVM.  191 
 192 
Growth on glycogen corresponded with variation in a putative pullulanase type I gene  193 
We followed-up on the glycogen growth experiments with a gene-trait analysis as glycogen is 194 
considered to be a key, although disputed, nutrient (directly) available to L. crispatus. We searched the L. 195 
crispatus genomes for the presence/absence of enzymes that can potentially be involved in glycogen 196 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/441972doi: bioRxiv preprint first posted online Oct. 13, 2018; 
7 
 
metabolism. We thus searched for orthologs of the: 1) glycogen debranching enzyme (encoded by glgX) 197 
in Escherichia coli [27, 28]; 2) Streptococcus agalactiae pullulanase [29]; 3) SusB of Bacteroides 198 
thetaiotaomicron [30]; and 4) the amylase (encoded by amyE) of Bacillus subtilis [31]. This search revealed 199 
a gene that was similar to the glgX gene; this gene was annotated as a pullulanase type I gene. In other 200 
species this pullulanase is bound to the outer S-layer of the cell wall, suggesting that this enzyme utilizes 201 
extracellular glycogen [32]. All except two strains (RL31, RL32) carried a copy of this gene. The genes are 202 
conserved except for variation in the N-terminal sequence that encodes a putative signal peptide that 203 
may be involved in subcellular localization of the enzyme.  All strains with less efficient growth on 204 
glycogen had a 29 amino acid deletion in the N-terminal sequence (strains: RL02, RL06, RL07, RL09, 205 
RL19 and RL26) and the strain that showed no growth (RL05) had an 8 amino acid deletion in the same 206 
region as the other strains in addition to 37 amino acid deletion further downstream (Table 3).  207 
 208 
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Key findings of this paper 212 
Here we report the full genomes of 28 L. crispatus clinical isolates; the largest contribution of L. crispatus 213 
clinical isolates to date. These strains were isolated from women with LVM and from women with DVM. 214 
A comparative genomics analysis revealed that a glycosyltransferase gene was more frequently found in 215 
the genomes of strains isolated from DVM as compared with strains isolated from LVM, suggesting a 216 
fitness advantage for carrying this gene in L. crispatus under dysbiotic conditions and a role of surface 217 
glycoconjugates in microbiota-host interactions. Comparative experiments pertaining to biofilm 218 
formation, antimicrobial activity and nutrient utilization showed that these two groups of strains did not 219 
phenotypically differ from each other. Of particular novelty value, we found that these clinical L. 220 
crispatus isolates were capable of growth on glycogen and that variation in a pullulanase type I gene 221 
correlates to the level of this activity.  222 
 223 
Vaginal dysbiotic conditions may pressurize Lactobacillus crispatus to vary its glycome   224 
Several studies have shown that vaginal dysbiosis is associated with an increased pro-inflammatory 225 
response, including an increase in pro-inflammatory chemokines and cytokines, but also elevated 226 
numbers of activated CD4+ T cells [3, 19], although no clinical signs of inflammation are present and 227 
vaginal dysbiosis is seen as a condition rather than as a disease [33]. Nonetheless, it indicates that the 228 
vaginal niche in a dysbiotic state is indeed under some immune pressure and that immune evasion could 229 
be a key (but poorly studied) trait for probiotic bacterial survival and dominance on the vaginal mucosa. 230 
 231 
Our comparative genomics analysis revealed a glycosyltransferase gene (GT) gene that was more 232 
common in strains isolated from DVM compared with strains isolated from LVM. The identified GT 233 
consists of three fragments, which all align to a single GT in the reference L. crispatus genome (ST1). 234 
Sequence analyses showed that the first and longest fragment exhibits close homology to a known GT-A 235 
fold and most probably harbors the active site of the GT (Figure 3). The latter two fragments do not 236 
harbor any structural motifs resembling known GTs and most probably do not harbor any catalytic GT 237 
activity. We hypothesize that these two fragments play a role in steering the specific activity of the GT 238 
(e.g. towards donor or substrate specificity). This might point towards L. crispatus harnessing its genetic 239 
potential to change its surface glycome. Such a process is termed phase variation and allows bacteria to 240 
rapidly adapt and diversify their surface glycans, resulting in an evolutionary advantage in the arms race 241 
between the immune system and invading bacteria. Modulation of the surface glycome by phase 242 
variation of the GT coding sequence is a common immune evasion strategy, which has been extensively 243 
studied in pathogenic bacteria like Campylobacter jejuni [25], but could be utilized by commensals as well 244 
[21]. We hypothesize that L. crispatus in DVM exploits this genetic variation to allow for (a higher) 245 
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variation in cell wall glycoconjugates providing a mechanism for L. crispatus to persist at low levels in 246 
DVM and remain stealth from the immune system (Figure 5). Of note, evidence for expression of all of 247 
the 3 GT-fragments  comes from a recent transcriptomics study that studied the effect of metronidazole 248 
treatment on the VM of women with (recurring) BV [11]. Personal communication with Dr. Zhi-Luo Deng 249 
revealed that high levels of expression for the three putative GT peptides were present in the vaginal 250 
samples of two women who were responsive to treatment (i.e. their VM was fully restored to a L. 251 
crispatus-dominated VM following treatment). This finding is in line with our hypothesis that the 252 
presence of the fragmented GT gene has a selective advantage for L. crispatus under dysbiotic 253 
conditions. Further functional experiments are needed to test this hypothesized host-microbe 254 
interaction and to coin if and how the variation of glycoconjugates is affected by this GT. Additionally, 255 
the immunological response of the host must be further studied in reference to these hypothesized 256 
microbial adaptations. The bacterial surface glycome and related variability events are currently 257 
overlooked features in probiotic strain selection, while they might be crucial to a strain’s survival and in 258 
vivo dominance [21].  259 
 260 
No distinct phenotypes pertaining to dominance in vivo were observed 261 
It has previously been postulated, relying merely on genomics data, that the accessory genome of L. 262 
crispatus could lead to strain differences relating to biofilm formation, adhesion and competitive 263 
exclusion of pathogens [9, 10]; all of which could influence whether a strain dominates the vaginal 264 
mucosa or not. Our comparative experimental work, however, showed that L. crispatus - irrespective of 265 
whether the strain was isolated from a woman with LVM or with DVM – all formed little to no biofilm, 266 
demonstrated effective lactic acid production and effective antimicrobial activity against N. 267 
gonorrhoeae. The previous genomic analyses also suggested that L. crispatus is herterofermentative [10]. 268 
Indeed, we observed that L. crispatus ferments a broad range of carbohydrates, as assessed by a 269 
commercial API test, but these profiles did not differ between strains isolated from LVM or from DVM.  270 
 271 
First evidence showing that Lactobacillus crispatus grows on glycogen  272 
The vaginal environment of healthy reproductive-age women is distinct from other mammals in that it 273 
has low microbial diversity, a high abundance of lactobacilli and high levels of lactic acid and luminal 274 
glycogen [34]. It has been postulated that proliferation of vaginal lactobacilli is supported by estrogen-275 
driven glycogen production [35], however the ‘fly in the ointment’ - as finely formulated by Nunn et al. 276 
[17] - is that  evidence for direct utilization of glycogen by vaginal lactobacilli is absent. Moreover, 277 
previous reports have stated that the core genome of L. crispatus does not contain the necessary 278 
enzymes to break down glycogen [10, 36]. It has even been suggested that L. crispatus relies on amylase 279 
secretion by the host or other microbes for glycogen breakdown [17, 37], as L. crispatus does contain all 280 
the appropriate enzymes to consume glycogen breakdown products such as glucose and maltose [36]. 281 
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Here we provide the first evidence suggesting that L. crispatus human isolates are capable of growing on 282 
extracellular glycogen and we identified variation in a gene which correlated with this activity. The 283 
identified gene putatively encodes a pullulanase type I enzyme belonging to the glycoside hydrolase 284 
family 13 [38]. Its closest ortholog is an extracellular cell-attached pullulanase found in L. acidophilus [32]. 285 
The L. crispatus pullulanase gene described here carries three conserved domains, comprising an N-286 
terminal carbohydrate-binding module family 41, a catalytic module belonging to the pullulanase super 287 
family and a C-terminal bacterial surface layer protein (SLAP) [39] (Figure 6). We observed that all except 288 
two of the strains in our study carry a copy of this gene. These two strains (RL31 and RL32), were no 289 
longer cultivable after their initial isolation. The six strains that showed less efficient or no growth on 290 
glycogen all showed variation in the N-terminal part of the pullulanase gene. All of these deletions are 291 
upstream of the carbohydrate-binding module in a sequence encoding a putative signal peptide. 292 
Furthermore, the presence of a SLAP-domain suggests that this enzyme is assigned to the outermost S-293 
layer of the cell wall and is hence expected to be capable of degrading extracellular glycogen [32]. 294 
Further functional experiments are needed to fully characterize this pullulanase enzyme and to assess 295 
whether it degrades intra- or extracellular glycogen. Importantly, this pullulanase is likely part of a larger 296 
cluster of glycoproteins involved in glycogen metabolism in L. crispatus, which should be considered in 297 
future research. 298 
 299 
Of note, we analyzed just one L. crispatus strain per vaginal sample, while it is plausible that multiple 300 
strain types co-exist in the vagina. So strain variability in growth on glycogen (and other carbohydrates) 301 
might actually benefit the L. crispatus population as a whole and explain the variation in growth on 302 
glycogen that we observed, especially considering that glycogen availability may fluctuate along with 303 
oscillating estrogen levels during the menstrual cycle. When developing probiotics, it could thus be 304 
beneficial to select for L. crispatus strains that ferment different carbohydrates (in addition to glycogen) 305 
[8] and also to supplement the probiotic with a prebiotic [40, 41].    306 
 307 
Conclusion 308 
Here we report whole-genome sequences of 28 L. crispatus human isolates. Our comparative study led 309 
to a total of three novel insights: 1) gene fragments encoding for a glycosyltransferase were 310 
disproportionally higher abundant among strains isolated from DVM, suggesting a role for cell surface 311 
glycoconjugates that shape vaginal microbiota-host interactions; 2) L. crispatus strains isolated from 312 
LVM do not differ from those isolated from DVM regarding the phenotypic traits studied here, including 313 
biofilm formation, pathogen inhibitory activity and carbohydrate utilization;  and 3) L. crispatus is able to 314 
grow on glycogen and this correlates with the presence of  a full-length pullulanase type I gene. 315 
  316 
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L. crispatus strain selection 318 
For this study, nurse-collected vaginal swabs were obtained from the Sexually Transmitted Infections 319 
clinic in Amsterdam, the Netherlands, from June to August 2012, as described previously by Dols et al. 320 
[4]. These vaginal samples came from women with LVM (Nugent score 0-3) and from women with DVM 321 
(Nugent score 7- 10). LVM and DVM vaginal swabs were plated on Trypton Soy Agar supplemented with 322 
5% sheep serum, 0.25% lactic acid and pH set to 5.5 with acetic acid and incubated under microaerobic 323 
atmosphere (using an Anoxomat; Mart Microbiology B.V., the Netherlands) at 37°C for 48-72 hours. 324 
Candidate Lactobacillus spp. strains were selected based on colony morphology (white, small, smooth, 325 
circular, opaque colonies) and single colonies were subjected to 16S rRNA sequencing. One L. crispatus 326 
isolate per vaginal sample was taken forward for whole genome sequencing. A DNA library was prepared 327 
for these isolates using the Nextera XT DNA Library preparation kit and the genome was sequenced 328 
using the Illumina Miseq generate FASTQ workflow.    329 
 330 
Genome assembly and quality control 331 
All analyses were run on a virtual machine running Ubuntu version 16.02. Contigs were assembled using 332 
the Spades assembly pipeline [42]. Contigs were discarded if they had less than 50% coverage with other 333 
assemblies or with the reference genome (N50 and NG50 values deviated more than 3 standard 334 
deviations from the mean as determined using QUAST [43]. The genomes were assembled with Spades 335 
3.5.0 using default settings. The Spades pipeline integrates read-error correction, iterative k-mer 336 
(nucleotide sequences of length k) based short read assembling and mismatches correction. The quality 337 
of the assemblies was determined with Quast (History 2013) using default settings and the Lactobacillus 338 
crispatus ST1 strain as reference genome (Genbank FN692037).  339 
 340 
Genome annotation and comparative genome analysis 341 
After assembly, the generated contigs were sorted with Mauve contig mover [44], using the L. crispatus 342 
ST1 strain as reference genome. Contaminating sequences of human origin and adaptor sequences were 343 
identified using BLAST and manually removed. The reordered genomes were annotated using the 344 
Prokka automated annotation pipeline [45] using default settings. Additionally, the genomes were 345 
uploaded to Genbank and annotated using the NCBI integrated Prokaryotic Genome Annotation 346 
Pipeline [46]. The annotated genomes were analyzed using the Sequence element enrichment analysis 347 
(SEER), which looks for an association between enriched k-mers and a certain phenotype [47]. Following 348 
the developer’s instructions, the genomes were split into k-mers using fsm-lite on standard settings and 349 
a minimum k-mer frequency of 2 and a maximum frequency of 28. The usage of k-mers enables the 350 
software to look for both SNPs as well as gene variation at the same time. After k-mer counting, the 351 
resulting file was split into 16 equal parts and g-zipped for parallelization purposes. In order to correct for 352 
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the clonal population structure of bacteria, the population structure was estimated using Mash with 353 
default settings [48]. Using SEER, we looked for k-mers of various lengths that associated with whether 354 
the L. crispatus strains came from LVM or DVM. The results were filtered for k-mers with a chi-square 355 
test of association of <0.01 and a likelihood-ratio test p-value (a statistical test for the goodness of fit for 356 
two models) of <0.0001. The resulting list of k-mers was sorted by likelihood-ratio p and the top 50 hits 357 
were manually evaluated using BLASTx and BLASTn. 358 
 359 
Pan and accessory genome analysis  360 
We used the bacterial pan genome analysis tool developed by Chaudhari et al. [49] using default 361 
settings. The circular image was created using CGview Comparison Tool [50] by running the 362 
build_blast_atlas_all_vs_all.sh script included in the package.   363 
 364 
Comparative phenotype experiments 365 
Not all strains were (consistently) cultivable after their initial isolation, so experimental data was 366 
collected for a subset of the strains and could differ per experiment. The ratio of cultivable LVM and 367 
DVM strains was however similar for each experiment. For a full overview of experimental procedures, 368 
we refer to the Supplementary Information. In short, carbohydrate metabolism profiles were assessed 369 
using commercial API CH50 carbohydrate fermentation tests (bioMérieux, Inc., Marcy l'Etoile, France) 370 
according to the manufacturer’s protocol. To assess organic acid production, strains were grown on 371 
medium that mimicked vaginal secretions [26]. Total metabolite extracts from spent medium were 372 
assessed as previously described by Collins et al. [41]. Biofilm formation was assessed using the crystal 373 
violet assay as described by Santos et al. [51] and auto-aggregation as described by Younes et al. [52]. 374 
Antimicrobial activity against Neisseria gonorrhoeae was assessed by challenging N. gonorrhoeae (WHO-375 
L strain) with varying (neutralized with NaOH to pH 7.0) dilutions of L. crispatus supernatants. Inhibitory 376 
effect was assessed as percentile difference in OD600nm in a conditional stationary phase as compared to 377 
the control.    378 
 379 
Glycogen degradation assay 380 
Starter cultures were grown in regular NYCIII glucose medium for 72 hours. For this assay, 1.1x 381 
carbohydrate deprived NYCIII medium was supplemented with water (negative control), 5% glucose 382 
(positive control) or 5% glycogen (Sigma-Aldrich, Saint Louis, US) and subsequently inoculated with 10% 383 
(v/v) bacterial culture (OD~0.5; 109 CFU/ml). Growth on glycogen was compared to growth on NYCII 384 
without supplemented carbon source and to NYCIII with glucose. Growth curves were followed in a 385 
BioScreen (Labsystems, Helsinki, Finland). At least two independent experiments per strain were 386 
performed in triplicate. 387 
  388 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/441972doi: bioRxiv preprint first posted online Oct. 13, 2018; 
13 
 
LIST OF ABBREVIATIONS 389 
VM: vaginal microbiota 390 
LVM: Lactobacillus-dominated vaginal microbiota  391 
DVM: dysbiotic vaginal microbiota 392 
COG: cluster ortholog genes 393 
GT: glycosyltransferase 394 
TSB: Trypton Soya Broth 395 
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Table 1. Overview and properties of 28 L. crispatus strains isolated from vaginal swabs with Lactobacillus-dominated vaginal microbiota or dysbiotic vaginal 
microbiota. 
Strain information Clinical information vaginal sample Pan-genome overview 
Accession no. ID Group Nugent score VM  
Cluster [4] 
Urogenital infection Genome  
size (Mb) 
GC content No. of core genes No. of accessory genes No. of unique genes 
NKLQ00000000 RL03 LVM 0 II None 2.52 36.86 1429 846 12 
NKLP00000000 RL05 LVM 0 II None 2.53 36.39 1429 553 243 
NKLO00000000 RL06 LVM 0 II None 2.16 36.92 1429 481 11 
NKLM00000000 RL08 LVM 0 I None 2.25 36.82 1429 606 43 
NKLL00000000 RL09 LVM 0 II None 2.25 36.83 1429 559 21 
NKLK00000000 RL10 LVM 0 I None 2.15 36.91 1429 612 31 
NKLJ00000000 RL11 LVM 0 II None 2.17 36.90 1429 482 5 
NKLF00000000 RL16 LVM 3 II None 2.56 36.49 1429 855 27 
NKKX00000000 RL26 LVM 3 II None 2.21 36.90 1429 525 103 
NKKW00000000 RL27 LVM 3 I None 2.51 36.84 1429 815 78 
NKKU00000000 RL29 LVM 2 II None 2.20 36.88 1429 501 44 
NKKR00000000 RL32 LVM 1 II CA 2.34 36.97 1429 644 63 
NKLR00000000 RL02 DVM 9 III None 2.22 36.88 1429 528 13 
NKLN00000000 RL07 DVM 10 IV None 2.16 36.94 1429 498 6 
NKLI00000000 RL13 DVM 9 V None 2.19 36.89 1429 488 28 
NKLH00000000 RL14 DVM 9 V None 2.56 36.76 1429 837 63 
NKLG00000000 RL15 DVM 8 V CT 2.27 36.79 1429 593 74 
NKLE00000000 RL17 DVM 8 III None 2.31 37.08 1429 605 250 
NKLD00000000 RL19 DVM 8 V None 2.41 36.93 1429 527 117 
NKLC00000000 RL20 DVM 10 III Candida 2.49 36.47 1429 660 41 
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NKLA00000000 RL23 DVM 10 III None 2.30 36.84 1429 621 1 
NKKZ00000000 RL24 DVM 9 III None 2.37 36.72 1429 682 9 
NKKY00000000 RL25 DVM 9 V None 2.32 36.84 1429 618 16 
NKKV00000000 RL28 DVM 10 IV None 2.17 36.88 1429 489 63 
NKKT00000000 RL30 DVM 10 IV None 2.27 36.76 1429 603 20 
NKKS00000000 RL31 DVM 10 IV CA 2.31 36.93 1429 652 48 
NKKQ00000000 RL33 DVM 8 I† TV 2.37 36.73 1429 631 31 
VM: vaginal microbiota; LVM: Lactobacillus-dominated VM; DVM: dysbiotic VM; CT: Chlamydia trachomatis; CA: Condylomata accuminata TV: Trichomonas 
vaginalis; VM clusters: I-L. iners; II-L. crispatus; III-G. vaginalis-Sneathia; IV-Sneathia-Lachnospiraceae; V-Sneathia 
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 Table 2. Comparison of distribution of glycosyltransferase (GT) gene fragments in Lactobacillus crispatus genomes isolated from vaginal samples with 
Lactobacillus-dominated or dysbiotic vaginal microbiota. 
 LVM 
N = 12 (%) 
DVM  
N = 16 (%) 
p-value* 
No GT fragments 6 (50.0) 3 (18.8) 0.114 





 GT fragment 1 (8.3) 0 (0.0) 0.429 
All 3 GT fragments 2 (16.6) 10 (62.5) 0.023 
LVM: Lactobacillus-dominated VM; DVM: dysbiotic VM  
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Table 3. Overview of Lactobacillus crispatus strain specific growth on glycogen and corresponding translated amino acid sequence at the N-terminal of a 
pullulanase type I gene.  
Strain ID Group Growth on glycogen Pullulanase Type I amino acid sequence (N-terminal) 
RL3 LVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL5 LVM - M________NKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAP_____________________________________PQNVPTVLAA 
RL6 LVM +/- M_____________________________SLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL8 LVM NA MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL9 LVM +/- M_____________________________SLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL10 LVM NA MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL11 LVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL16 LVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL22† LVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL26 LVM +/- M_____________________________SLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL27 LVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL29 LVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL32 LVM NC --------------------------------------------------------------------------------------------------- 
RL2 DVM +/- M_____________________________SLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL7 DVM +/- M_____________________________SLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL13 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL14 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL15 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL17 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL19 DVM EL M_____________________________SLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL20 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL21 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
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RL24 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL25 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL28 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL30 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
RL31 DVM NC --------------------------------------------------------------------------------------------------- 
RL33 DVM + MILWRNLFMNKKSGHNIKFKSIFVCTSAIMSLWLGANLTTTQVHAAEDNAAPKSSEVVGQTNSSKDNAATATVQNQSNAKAKQRQQGVAPQNVPTVLAA 
LVM: Lactobacillus-dominated vaginal microbiota; DVM: dysbiotic vaginal microbiota; NA: not available; NC: non-cultivable; EL: extended lag time. 
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Figure 1. Whole genome alignments of the coding sequences from the Lactobacillus crispatus 
clinical isolates described in this study. The outermost ring represents COG annotated genes on the 
forward strand (color coded according to the respective COG). The positions of the genes discussed in 
this article are indicated. The third ring represents COG annotated genes on the reverse strand (color 
coded according to the respective COG). The next twelve rings each represent one genome of the LVM 
strains, followed by a separator ring and 16 rings each representing a genome of the DVM strains. The 
height of the bar and the saturation of the color in these rings indicate a BLAST hit of either >90% 
identity (darker colored) or >70% identity (lightly colored). Hits below 70% identity score are not shown 
and appear as white bars in the plots. The two inner most rings represent the GC content of that area 
and the GC-skew respectively. The presence or absence of the gene variants discussed in this article is 
indicated in each genome by black and white dots. A black dot indicates that a wild-type gene (as 
compared to the STI reference genome) is present in that genome, a white dot indicates that no copy of 
that gene (fragment) was present or that it carried a deletion (for the type 1 pullulanase). Abbreviations: 
COG: cluster ortholog genes; LVM: Lactobacillus-dominated vaginal microbiota; DVM: dysbiotic vaginal 
microbiota; WT: wild type. 
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Figure 2. Schematic overview of the organization of the glycosyltransferase fragments in the 
Lactobacillus crispatus genomes. The orientation of the fragments is dependent on the assembly, and 
can therefore be different than depicted here. Also, the distance between the fragments is 
undetermined and can be of any length (depicted with diagonal lines). Abbreviations: GT: 
Glycosyltransferase; GTA, GTB: GT super families; GT1, GT2, GT3: GT fragments 1, 2, 3; UDP-GALAC: 
UDP-Galactopyranose mutase; GTF: GT family 1; TRAN: transposase; LVM: Lactobacillus-dominated 
vaginal microbiota; DVM: dysbiotic vaginal microbiota. 
 
  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/441972doi: bioRxiv preprint first posted online Oct. 13, 2018; 
Figure 3. Schematic overview of how the glycosyltransferase fragments align to the Lactobacillus 
crispatus ST1 reference genome. The first fragment comprises the conserved glycosyltransferase 
family 2 domain with catalytic activity. The shorter second and third fragments most probably do not 
harbor any catalytic GT activity. We hypothesize that these two fragments play a role in steering the 
specific activity of the GT (e.g. towards donor or substrate specificity). Abbreviation: GT: 
glycosyltransferase.  
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Figure 4. Growth on glycogen for Lactobacillus crispatus strains isolated from Lactobacillus-
dominated and from dysbiotic vaginal microbiota. Strains were grown in minimal medium 
supplemented with A) 5% glucose and B) 5% glycogen. Strains that showed less efficient or no growth 
on glycogen carried a mutation in the N-terminal sequence of a putative type I pullulanase gene. RL19 
showed a longer lag time compared to other strains; on average 4.5 hours, compared to an average of 
1.5 hours for other strains. Abbreviations: LVM: Lactobacillus-dominated vaginal microbiota; DVM: 
dysbiotic vaginal microbiota; WT: wild type. 
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Figure 5. Model for enzymatic activity in glycosylation and glycogen degradation in Lactobacillus 
crispatus. Schematic representation of the vaginal environment with either LVM or DVM. Our 
comparative genomics analysis revealed a glycosyltransferase gene that was more common in 
Lactobacillus crispatus strains isolated from LVM (red bacteria) and DVM (low abundance of red 
lactobacilli, diverse bacterial population in multiple colors and forms, thinner mucus layer). We 
hypothesize that L. crispatus in DVM exploits this genetic variation to allow for (a higher) variation in cell 
wall glycoconjugates providing a mechanism for L. crispatus to persist at low levels in DVM and remain 
stealth from the immune system. Another finding of this work describes the ability of L. crispatus strains 
to utilize glycogen as a food source, which is associated with the presence of a full-length pullulanase 
gene (red dots on cell wall of L. crispatus). Abbreviations: LVM: Lactobacillus-dominated vaginal 
microbiota; DVM: dysbiotic vaginal microbiota, LC: Langerhans cell, CK: cytokines. 
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Figure 6. Schematic overview of the organization of the putative pullulanase type I encoding gene in 
Lactobacillus crispatus. The enzyme comprises three conserved domains including an N-terminal 
carbohydrate-binding module family 41 with specific carbohydrate binding sites, a catalytic module 
belonging to the pullulanase super family and a C-terminal bacterial surface layer protein (SLAP). The 
mutations (indicated by arrows) were located in an unconserved area that encodes a putative signal 
peptide (SP) that may be involved in subcellular localization. Abbreviations: SP: signal peptide; CBM41: 
carbohydrate-binding module family 41; PulA: pullulanase; SLAP: surface layer protein. 
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